Huseby DL

Antibiotic class with potent in vivo activity targeting lipopolysaccharide synthesis in Gram-negative bacteria.

Huseby DL, Cao S, Zamaratski E, ..., Hughes D, Karlén A

Proc. Natl. Acad. Sci. U.S.A. 121 (15) e2317274121 [2024-04-09; online 2024-04-05]

Drug Discovery and Development (DDD) [Collaborative]

New Dual Inhibitors of Bacterial Topoisomerases with Broad-Spectrum Antibacterial Activity and In Vivo Efficacy against Vancomycin-Intermediate Staphylococcus aureus.

Durcik M, Cotman AE, Toplak Ž, ..., Tomašič T, Peterlin Mašič L

J. Med. Chem. 66 (6) 3968-3994 [2023-03-23; online 2023-03-06]

Drug Discovery and Development (DDD) [Service]

Discovery and Hit-to-Lead Optimization of Benzothiazole Scaffold-Based DNA Gyrase Inhibitors with Potent Activity against Acinetobacter baumannii and Pseudomonas aeruginosa.

Cotman AE, Durcik M, Benedetto Tiz D, ..., Sterk GJ, Kikelj D

J. Med. Chem. 66 (2) 1380-1425 [2023-01-26; online 2023-01-12]

Drug Discovery and Development (DDD) [Service]